The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients
Li et al.
, The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe..
, International Immunopharmacology, doi:10.1016/j.intimp.2021.107531
Retrospective 311 severe condition hospitalized patients in China, 123 treated with probiotics, showing slower viral clearance and recovery with treatment. Authors note that probiotics were able to moderate immunity and decrease the incidence of secondary infections.
The immune effects of probiotics are strain-specific.
risk of no hospital discharge, 11.8% higher, RR 1.12, p = 0.68, treatment 30 of 123 (24.4%), control 41 of 188 (21.8%).
time to discharge, 60.0% higher, relative time 1.60, p < 0.001, treatment 123, control 188.
time to viral-, 35.3% higher, relative time 1.35, p < 0.001, treatment 123, control 188.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 5 Mar 2021, retrospective, China, peer-reviewed, 7 authors, average treatment delay 13.0 days.
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
International Immunopharmacology 95 (2021) 107531
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/intimp
The role of probiotics in coronavirus disease-19 infection in Wuhan: A
retrospective study of 311 severe patients
Qiang Li 1, Fang Cheng 1, Qiling Xu , Yuyong Su , Xuefeng Cai , Fang Zeng *, Yu Zhang *
Department of Pharmacy, Union Hospital, Tongji Medical College, Hua Zhong University of Science and Technology, Wuhan 430022, China
Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan 430022, China
A R T I C L E I N F O
A B S T R A C T
Purpose: Researches revealed that probiotics maybe a potential strategy for COVID-19, whereas there is a lack of
related evidence. This study aims to analyze the role of probiotics on severe COVID-19 patients.
Methods: In the current retrospective single-center study, we collected data of 311 consecutive severe patients
with confirmed COVID-19 in Wuhan Union Hospital from Feb 3rd to Feb 20th, 2020. Epidemiological, clinical
and medication characteristics were compared and analyzed between patients with or without probiotics.
Results: In total, 93 of the 123 patients (75.61%) who were treated with probiotics survived to hospital discharge
with the median inpatient day of 32 days and mean virus clearance time of 23 days, which were significantly
longer than those of patients without probiotics. There were no bias in laboratory parameters, except for IL-6 and
ESR, which were significantly higher in patients treated probiotics. We tracked the dynamic changes of 8 selected
laboratory parameters (IL-6, CRP, total T lymphocytes, NK cells, B lymphocyte, CD4 + T cells, CD8 + T cells and
CD4/CD8 ratio) and found that probiotics could not reduce the increased IL-6 levels but possessed the ability to
moderate the immunity and decreased the incidence of secondary infection in COVID-19 patients.
Conclusions: Probiotics could be an effective strategy for the treatment of COVID-19 patients to reduce the
secondary infection and moderated the immunity.
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.